A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

Completed · Not applicable

Conditions studied: Lymphoma, Non-Hodgkin, HIV Infections

In brief

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

Key facts

Study ID

NCT00002284

Run by

Glaxo Wellcome

Last updated by the study team

2005-06-24

Who can join

Age: 12 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Co-existing Condition:
• Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
• Concurrent Medication:
• Excluded:
• Other anti-retroviral agents.
• Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
• Patients must be:
• HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
• At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
• Also patient must fall into one of the following categories:
• Have an HIV seronegative identical twin to serve as a bone marrow donor.
• Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
• Be a good risk candidate for bone marrow transplant.

Where it is running

• Johns Hopkins Hemapheresis Treatment Ctr — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.